10 Best Prefered Stocks To Own For 2016

10 Best Prefered Stocks To Own For 2016: Enzon Pharmaceuticals Inc. (ENZN)

Enzon Pharmaceuticals, Inc., a biotechnology company, engages in the research and development of therapeutics for cancer patients with unmet medical needs. The company?s drug-development programs utilize two platforms-Customized PEGylation Linker Technology and third-generation mRNA-targeting agents utilizing the Locked Nucleic Acid (LNA) technology. It currently holds four compounds in clinical development and multiple novel LNA targets in preclinical research. The company?s development product pipeline consists of PEG-SN38 compound that utilizes Customized Linker Technology, which is in Phase II clinical trials for the treatment of metastatic colorectal and breast cancer, as well as a Phase I trial for pediatric patients with cancer; and the Hypoxia-Inducible Factor-1 alpha antagonist in Phase I studies for the treatment of solid tumors and lymphoma. Its product line also comprises Survivin antagonist in Phase I study in pediatric patients with recurrent acute lymphoblas tic leukemia; Androgen Receptor antagonist, a validated target for the treatment of prostate cancer that is in a Phase I study in patients with castration-resistant prostate cancer; and rights to five compounds, including AR, HER3, beta-catenin, PI3KCA, and Gli2. Enzon Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Piscataway, New Jersey.

Advisors' Opinion:

• [By Monica Wolfe]

  Over the past week Seth Klarman (Trades, Portfolio) of The Baupost Group made one real time reduction; the guru reduced his holdings in Enzon Pharmaceutical (ENZN). The guru cut his holdings in the company -43.6% by selling 3,353,595 shares of the companys stock. He sold these shares at an average price of $1.15 per share; the shares are still currently trading at around the same price.

• [By Lisa Levin]

  Enzon Pharmaceuticals (NASDAQ: ENZN) shares fell 2.57% to touch a new 52-week low of $1.11. Enzon ! Pharmaceuticals shares have dropped 75.85% over the past 52 weeks, while the S&P 500 index has gained 24.92% in the same period.

• [By Bryan Murphy]

  With just a quick glance at the company's recent news (or lack thereof), Enzon Pharmaceuticals Inc. (NASDAQ:ENZN) doesn't look like anything all that special... or even trade-worthy. It only takes a brief look at the chart of ENZN, however, to conclude this stock - lack of new or not - has just become something trade-worthy, because the rest of the market has clearly started to fall back in love with it; there's no telling at what price the love affair could end.

• [By Lisa Levin]

  Enzon Pharmaceuticals (NASDAQ: ENZN) shares tumbled 28.28% to reach a new 52-week low of $1.15. Enzon Pharmaceuticals shares have dropped 63.30% over the past 52 weeks, while the S&P 500 index has gained 28.75% in the same period.

source from Top Stocks To Buy For 2015:http://www.topstocksforum.com/10-best-prefered-stocks-to-own-for-2016.html